Emi Funayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emi Funayama has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Kosuke Ishikawa
Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan
5 shared publications - Taku Maeda
Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan
5 shared publications - Takahiro Miura
Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
3 shared publications Yuhei Yamamoto
Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
3 shared publicationsAkihiko Oyama
2 shared publications- Dongkyung Seo
Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, Japan
2 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Georg Thieme Verlag KG in Archives of Plastic Surgery
- Vol. 53 (03) , 299-309
The Omentum as a Lymphoid Tissue: Its Molecular Aspects and Application in a Murine Model
The omentum is a vascularized, immune-active tissue with regenerative potential, particularly when activated by intraperitoneal stimuli. Its secreted factors may promote lymphangiogenesis, offering a novel approach to lymphedema treatment. The omentum was activated in mice using an intraperitoneal polydextran slurry. Gene expression was evaluated over time to assess inflammatory and lymphatic markers. Culture supernatants from the activated omentum were collected, and vascular endothelial growth factor-C (VEGF-C) levels were measured. Therapeutic potential was tested in a mouse hindlimb lymphedema model through local application of the supernatant. Histological analysis assessed skin thickness, lymphatic vessel density, and macrophage infiltration. Activation of the omentum induced early upregulation of hypoxia-inducible factor-1 α (HIF-1α) and angiopoietin-2 (Ang2), followed by increased expression of Forkhead Box C2 (Foxc2) and Prospero homeobox-1 (Prox1) by day 7, indicating lymphatic maturation. VEGF-C levels in the supernatant were significantly elevated. In the lymphedema model, treated mice exhibited reduced peak edema, faster resolution, and increased skin thickness and lymphatic vessel density compared with controls. Histological analysis revealed enhanced lymphangiogenesis and reduced macrophage infiltration. Downregulation of lymphatic vessel endothelial hyaluronan receptor 1 (Lyve1) and Neuropilin-1 (NRP1) suggested a predominance of tissue remodeling over structural maintenance. Activated omental tissue secretes potent bioactive factors that promote lymphangiogenesis and tissue regeneration. These findings indicate the potential of activated omentum for functional characterization and possible applications in regenerative medicine. Further investigation in chronic and clinical models is warranted to advance its translational potential.
- 29 May 2026
- Published by Georg Thieme Verlag KG in Archives of Plastic Surgery
- Vol. 53 (03) , 299-309
Open AccessThe Omentum as a Lymphoid Tissue: Its Molecular Aspects and Application in a Murine Model
The omentum is a vascularized, immune-active tissue with regenerative potential, particularly when activated by intraperitoneal stimuli. Its secreted factors may promote lymphangiogenesis, offering a novel approach to lymphedema treatment. The omentum was activated in mice using an intraperitoneal polydextran slurry. Gene expression was evaluated over time to assess inflammatory and lymphatic markers. Culture supernatants from the activated omentum were collected, and vascular endothelial growth factor-C (VEGF-C) levels were measured. Therapeutic potential was tested in a mouse hindlimb lymphedema model through local application of the supernatant. Histological analysis assessed skin thickness, lymphatic vessel density, and macrophage infiltration. Activation of the omentum induced early upregulation of hypoxia-inducible factor-1 α (HIF-1α) and angiopoietin-2 (Ang2), followed by increased expression of Forkhead Box C2 (Foxc2) and Prospero homeobox-1 (Prox1) by day 7, indicating lymphatic maturation. VEGF-C levels in the supernatant were significantly elevated. In the lymphedema model, treated mice exhibited reduced peak edema, faster resolution, and increased skin thickness and lymphatic vessel density compared with controls. Histological analysis revealed enhanced lymphangiogenesis and reduced macrophage infiltration. Downregulation of lymphatic vessel endothelial hyaluronan receptor 1 (Lyve1) and Neuropilin-1 (NRP1) suggested a predominance of tissue remodeling over structural maintenance. Activated omental tissue secretes potent bioactive factors that promote lymphangiogenesis and tissue regeneration. These findings indicate the potential of activated omentum for functional characterization and possible applications in regenerative medicine. Further investigation in chronic and clinical models is warranted to advance its translational potential.
- 24 January 2025
- Published by SAGE Publications in Advances in Wound Care
- Vol. 15 (4) , 218-227
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat Accelerates Wound Healing in a Mouse Hind limb Lymphedema Model
Objective: Drugs regulating hypoxia-inducible factor (HIF)-1α have not been investigated for wound healing in lymphedema. Therefore, we examined the effects of drug modulation of HIF-1α activity for wound healing in our previously developed mouse model of nonirradiated hind limb lymphedema. Approach: Mouse hind limb lymphedema models ( n = 17) and a sham group ( n = 6) were created using 8- to 10-week-old male C57BL/6N mice. Mice with hind limb lymphedema were randomized into experimental groups receiving roxadustat, 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1), or dimethyl sulfoxide and were given intraperitoneal injections every 2 days for up to 2 weeks. Four days after the surgery, an 8-mm diameter full-thickness skin wound was created in the hind limb. The number of days required for wound closure and the percentage of wounds closed were measured. Skin samples taken at wound creation were evaluated by histological and molecular analysis. Results: Administration of roxadustat accelerated wound healing, whereas YC-1 delayed it, with a significant decrease and increase in skin thickness, respectively. The relative mRNA expression of Hif1α , matrix metalloproteinase-3 , and interleukin-6 was significantly higher in the roxadustat group and that of metalloproteinase-9 was significantly lower in the roxadustat group compared with the control group. Innovation: This study is the first to demonstrate delayed wound healing in a mouse model of hind limb lymphedema and the first to demonstrate the promotion of significant wound healing through the use of roxadustat. Conclusion: Roxadustat exerts wound-healing effects and may promote the regulation of extracellular matrix remodeling via gene expression in hind limb lymphedema wound models.
- 24 January 2025
- Published by SAGE Publications in Advances in Wound Care
- Vol. 15 (4) , 218-227
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat Accelerates Wound Healing in a Mouse Hind limb Lymphedema Model
Objective: Drugs regulating hypoxia-inducible factor (HIF)-1α have not been investigated for wound healing in lymphedema. Therefore, we examined the effects of drug modulation of HIF-1α activity for wound healing in our previously developed mouse model of nonirradiated hind limb lymphedema. Approach: Mouse hind limb lymphedema models ( n = 17) and a sham group ( n = 6) were created using 8- to 10-week-old male C57BL/6N mice. Mice with hind limb lymphedema were randomized into experimental groups receiving roxadustat, 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole (YC-1), or dimethyl sulfoxide and were given intraperitoneal injections every 2 days for up to 2 weeks. Four days after the surgery, an 8-mm diameter full-thickness skin wound was created in the hind limb. The number of days required for wound closure and the percentage of wounds closed were measured. Skin samples taken at wound creation were evaluated by histological and molecular analysis. Results: Administration of roxadustat accelerated wound healing, whereas YC-1 delayed it, with a significant decrease and increase in skin thickness, respectively. The relative mRNA expression of Hif1α , matrix metalloproteinase-3 , and interleukin-6 was significantly higher in the roxadustat group and that of metalloproteinase-9 was significantly lower in the roxadustat group compared with the control group. Innovation: This study is the first to demonstrate delayed wound healing in a mouse model of hind limb lymphedema and the first to demonstrate the promotion of significant wound healing through the use of roxadustat. Conclusion: Roxadustat exerts wound-healing effects and may promote the regulation of extracellular matrix remodeling via gene expression in hind limb lymphedema wound models.
- Open Access
- 30 June 2024
- Published by Korean Wound Management Society in Journal of Wound Management and Research
- Vol. 20 (2) , 168-172
Leukocytoclastic Vasculitis-Induced Lower Leg Ulceration in the Course of Immune Checkpoint Inhibitor Therapy for Advanced Malignant Melanoma: A Case Report
Immune checkpoint inhibitors (ICIs) have expanded therapeutic options for advanced malignancies, offering new hope for conditions once deemed untreatable. However, the advent of ICIs has introduced a spectrum of immune-related adverse events (irAEs), including leukocytoclastic vasculitis (LCV), a rare but significant complication. This case report describes development of LCV after treatment with nivolumab and ipilimumab in a 70-year-old man with malignant melanoma, highlighting the diagnostic and management challenges of such irAEs. Despite extensive investigation, conventional pathology failed to identify the immune complexes typically associated with LCV. The clinical presentation, alongside a detailed medical history and the exclusion of infections, medications, and autoimmune diseases, was crucial in establishing a diagnosis. Ulcer resolution following discontinuation of ICI therapy and initiation of steroids further support the conclusion that LCV was an irAE in this patient. This case underscores the need for vigilant monitoring for irAEs for the variable onset after ICI therapy and the importance of thorough history-taking to guide diagnosis and treatment. With ICIs becoming increasingly prevalent in oncology, the incidence of ICI-induced ulcers like LCV is expected to rise, necessitating heightened awareness and multidisciplinary approaches to patient care.
- 30 June 2024
- Published by Korean Wound Management Society in Journal of Wound Management and Research
- Vol. 20 (2) , 168-172
Open AccessLeukocytoclastic Vasculitis-Induced Lower Leg Ulceration in the Course of Immune Checkpoint Inhibitor Therapy for Advanced Malignant Melanoma: A Case Report
Immune checkpoint inhibitors (ICIs) have expanded therapeutic options for advanced malignancies, offering new hope for conditions once deemed untreatable. However, the advent of ICIs has introduced a spectrum of immune-related adverse events (irAEs), including leukocytoclastic vasculitis (LCV), a rare but significant complication. This case report describes development of LCV after treatment with nivolumab and ipilimumab in a 70-year-old man with malignant melanoma, highlighting the diagnostic and management challenges of such irAEs. Despite extensive investigation, conventional pathology failed to identify the immune complexes typically associated with LCV. The clinical presentation, alongside a detailed medical history and the exclusion of infections, medications, and autoimmune diseases, was crucial in establishing a diagnosis. Ulcer resolution following discontinuation of ICI therapy and initiation of steroids further support the conclusion that LCV was an irAE in this patient. This case underscores the need for vigilant monitoring for irAEs for the variable onset after ICI therapy and the importance of thorough history-taking to guide diagnosis and treatment. With ICIs becoming increasingly prevalent in oncology, the incidence of ICI-induced ulcers like LCV is expected to rise, necessitating heightened awareness and multidisciplinary approaches to patient care.
- 1 January 2023
- Published by Undersea and Hyperbaric Medical Society (UHMS) in Undersea and Hyperbaric Medicine
- Vol. 50 (4) , 413-419
Efficacy of hyperbaric oxygen after microtia reconstruction using costal cartilage: A retrospective case-control study
Introduction: Microtia reconstruction with autologous costal cartilage framework grafting is challenging because the three-dimensional structure of the ear is highly complex, and meeting the high aesthetic demands of patients can be difficult. If the skin flap overlying the framework is thinned to achieve a smooth and accentuated outline, a poor blood supply in the thin skin flap may lead to skin necrosis, exposure of the framework, and poor surgical results. Hyperbaric oxygen (HBO2) therapy can promote the healing of complex wounds and flaps. This study sought to determine the effectiveness of HBO2 therapy for prevention of postoperative complications after framework grafting in microtia reconstruction. Methods: We retrospectively evaluated postoperative complications and compared outcomes in pediatric patients who underwent costal cartilage grafting for microtia reconstruction at our institution between 2011 and 2015 according to whether or not they received postoperative HBO2 therapy. HBO2 therapy was applied once daily for a total of 10 sessions starting on the first postoperative day. Results: During the study period, eight patients received HBO2 therapy after costal cartilage grafting and 12 did not. There was no significant difference in the incidence of postoperative ulcers. However, the incidence of framework exposure was lower and the healing time was shorter in patients who received HBO2 therapy than in those who did not. Discussion: HBO2 therapy can be used safely in pediatric patients to reduce postoperative complications and improve the aesthetic outcome of microtia reconstruction. After costal cartilage grafting, HBO2 therapy should be considered as adjuvant therapy.
- 1 January 2023
- Published by Undersea and Hyperbaric Medical Society (UHMS) in Undersea and Hyperbaric Medicine
- Vol. 50 (4) , 413-419
Efficacy of hyperbaric oxygen after microtia reconstruction using costal cartilage: A retrospective case-control study
Introduction: Microtia reconstruction with autologous costal cartilage framework grafting is challenging because the three-dimensional structure of the ear is highly complex, and meeting the high aesthetic demands of patients can be difficult. If the skin flap overlying the framework is thinned to achieve a smooth and accentuated outline, a poor blood supply in the thin skin flap may lead to skin necrosis, exposure of the framework, and poor surgical results. Hyperbaric oxygen (HBO2) therapy can promote the healing of complex wounds and flaps. This study sought to determine the effectiveness of HBO2 therapy for prevention of postoperative complications after framework grafting in microtia reconstruction. Methods: We retrospectively evaluated postoperative complications and compared outcomes in pediatric patients who underwent costal cartilage grafting for microtia reconstruction at our institution between 2011 and 2015 according to whether or not they received postoperative HBO2 therapy. HBO2 therapy was applied once daily for a total of 10 sessions starting on the first postoperative day. Results: During the study period, eight patients received HBO2 therapy after costal cartilage grafting and 12 did not. There was no significant difference in the incidence of postoperative ulcers. However, the incidence of framework exposure was lower and the healing time was shorter in patients who received HBO2 therapy than in those who did not. Discussion: HBO2 therapy can be used safely in pediatric patients to reduce postoperative complications and improve the aesthetic outcome of microtia reconstruction. After costal cartilage grafting, HBO2 therapy should be considered as adjuvant therapy.